The company’s head of oncology, Dave Fredrickson, said the approval of Truqap “reinforces the important role of the PI3K/AKT pathway in HR-positive breast cancer and the critical need to test ...

Our laboratory is dedicated to understanding the consequences of activation of these pathways and to using this information to develop mechanism-based therapeutic strategies. The laboratory is ...

The researchers treated the cells with varying concentrations of cordycepin and compared them to cells treated with known inhibitors of specific kinases in the MEK/ERK and PI3K/AKT/mTOR pathways.

Kazia Therapeutics ( (KZIA) ) has provided an announcement.